Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2.
about
Development of a serum-free co-culture of human intestinal epithelium cell-lines (Caco-2/HT29-5M21).Antifungal activity of redox-active benzaldehydes that target cellular antioxidation.Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models.Current industrial practices of assessing permeability and P-glycoprotein interactionToxicity of cylindrospermopsin, and other apparent metabolites from Cylindrospermopsis raciborskii and Aphanizomenon ovalisporum, to the zebrafish (Danio rerio) embryo.In vitro models for processes involved in intestinal absorption.Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.Modeling kinetics of subcellular disposition of chemicals.Intestinal permeability and P-glycoprotein-mediated efflux transport of ticagrelor in Caco-2 monolayer cells.Water-soluble organic solubilizers for in vitro drug delivery studies with respiratory epithelial cells: selection based on various toxicity indicators.Shape effect in the design of nanowire-coated microparticles as transepithelial drug delivery devicesTransepithelial Transport of Curcumin in Caco-2 Cells Is significantly Enhanced by Micellar Solubilisation.Tanshinone IIA increases mRNA expression of efflux transporters in cultured human intestinal cell.An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity.pH dependent uptake of loperamide across the gastrointestinal tract: an in vitro study.Using Human Plasma as an Assay Medium in Caco-2 Studies Improves Mass Balance for Lipophilic Compounds
P2860
Q33241981-CFFA7E2F-5672-452D-A1F0-DFB01ED4DB94Q35081105-161FD2D4-A9BF-4DF9-A80E-BAA5AACD61E2Q36295334-7810821A-7F54-4FC2-ABC6-63BACBCCD20EQ36439145-B5356A31-4C1B-41B8-85F9-4DF6D84A10E1Q36441666-00DFB6C8-0B88-40E3-89F1-B92766236105Q36909324-A2CE7373-6127-4646-AC82-AC361B9A75E2Q37058658-B002E04D-BF16-4BE1-B944-A4C8CBB928F4Q37194304-EB08B70B-78B8-4DA3-B302-08FC26AB38E3Q38758204-36544ECC-2CD0-40FA-A34D-54AE1EF8470AQ39709278-A92BA700-44C6-438A-AD3A-A873E965A888Q41808104-EBC82445-25EC-4E2C-8449-0B5EC384D3BBQ42319897-338B3AD6-E2C6-4632-8246-48B8145EC829Q42915310-AE64D329-63C8-40F5-BC24-7D3E8A999BC1Q43453290-3BAC2046-51D0-4171-A5BF-35A6C8B6A907Q44970973-EC4C6081-6BFB-4C22-9D85-E6CC3FC09908Q58731266-67275451-152E-4D1A-A73A-589EF6EF57F0
P2860
Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Biological, pharmaceutical, an ...... tion screening system, Caco-2.
@ast
Biological, pharmaceutical, an ...... tion screening system, Caco-2.
@en
type
label
Biological, pharmaceutical, an ...... tion screening system, Caco-2.
@ast
Biological, pharmaceutical, an ...... tion screening system, Caco-2.
@en
prefLabel
Biological, pharmaceutical, an ...... tion screening system, Caco-2.
@ast
Biological, pharmaceutical, an ...... tion screening system, Caco-2.
@en
P356
P1476
Biological, pharmaceutical, an ...... tion screening system, Caco-2.
@en
P2093
Françoise M Ingels
Patrick F Augustijns
P304
P356
10.1002/JPS.10408
P407
P577
2003-08-01T00:00:00Z